not tagged
not tagged
['lymsm', 'lymphoma']
#eha2022 | john radford, , presented phase iii data supporting a+avd as a superior option for previously untreated stage iii and iv chl. there was a 41% reduction in the risk of death with a+avd vs abvd, and benefit across prespecified subgroups #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm